Drugs / INCB106385
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04989387 | Oct 2021 → Sep 2024 | digestive system cancer, head and neck squamous cell carcinoma | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT04580485 | Feb 2021 → Jan 2024 | anal canal squamous cell carcinoma, castration-resistant prostate carcinoma, gastroesophageal cancer, head and neck squamous cell carcinoma +6 | Incyte Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB106385 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04580485 ↗ |
| Action | Inhibit | “a potent dual A2A/A2B antagonist” PMID 42201333 ↗ May 2026 |
| Route | Oral | “INCB106385 will be administered orally QD” NCT04580485 ↗ |